Breaking the cycle: How immune reprogramming and modulation are redefining Osteoarthritis care

Area of Science:

• Immunology
• Rheumatology
• Biomedical Engineering

Background:

• Osteoarthritis (OA) is now understood as an immune-mediated condition, not just mechanical wear.
• Immune dysregulation, particularly M1 macrophages, drives joint inflammation and cartilage damage in OA.
• Autoimmune aspects and ectopic lymphoid structures suggest complex immune involvement in OA subsets.

Purpose of the Study:

• To review the immunological basis of osteoarthritis.
• To evaluate the potential of immune reprogramming therapies for OA.
• To identify research needs for clinical translation of immune-centric OA treatments.

Main Methods:

• Review of recent findings on OA immunology.
• Assessment of preclinical data on hydrogel microsphere-mediated macrophage reprogramming.
• Analysis of challenges and future directions for clinical application.

Main Results:

• Preclinical studies show hydrogel microspheres can reprogram M1 macrophages to M2 phenotype with high efficiency (up to 88.5%).
• This reprogramming diminishes inflammation and preserves cartilage integrity in OA models.
• Significant clinical hurdles include patient tailoring, targeting accuracy, and sustained efficacy.

Conclusions:

• Immune reprogramming represents a promising therapeutic strategy for OA.
• Understanding immune mechanisms can lead to disease-modifying immunotherapies and improved patient stratification.
• Advanced techniques like single-cell RNA sequencing can enable tailored immune regulation for potentially reversible OA treatments.